Cartesian Therapeutics, Inc.
RNAC
$8.84
$0.121.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -92.91% | 224.77% | 16.80% | -99.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -92.91% | 224.77% | 16.80% | -99.11% |
| Cost of Revenue | 37.41% | 32.64% | 29.92% | 21.07% | 17.44% |
| Gross Profit | -40.22% | -42.81% | -13.90% | -21.22% | -170.11% |
| SG&A Expenses | 20.50% | -14.44% | 15.66% | 17.59% | 3.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.87% | 15.61% | 24.43% | 19.80% | 12.30% |
| Operating Income | -33.67% | -21.06% | -14.55% | -19.86% | -258.54% |
| Income Before Tax | -0.74% | -121.24% | -921.16% | -48.46% | 14.82% |
| Income Tax Expenses | -- | -- | -3,303.14% | -- | -- |
| Earnings from Continuing Operations | -0.74% | -121.24% | -802.92% | -48.46% | 14.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.74% | -121.24% | -802.92% | -48.46% | 14.82% |
| EBIT | -33.67% | -21.06% | -14.55% | -19.86% | -258.54% |
| EBITDA | -33.71% | -24.84% | -14.28% | -18.34% | -252.10% |
| EPS Basic | -8.76% | -137.84% | -782.64% | -22.59% | -11.36% |
| Normalized Basic EPS | -51.84% | -35.76% | -12.26% | -72.73% | -210.22% |
| EPS Diluted | -8.00% | -137.84% | -783.46% | -22.59% | -7.41% |
| Normalized Diluted EPS | -52.51% | -35.76% | -12.26% | -72.73% | -215.22% |
| Average Basic Shares Outstanding | 13.42% | 3.53% | 2.30% | 21.10% | 55.35% |
| Average Diluted Shares Outstanding | 12.91% | 3.53% | 2.30% | 21.10% | 48.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |